MarketPulse

wet AMD

6 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Eyepoint, Inc.

EyePoint Faces Revenue Collapse as DURAVYU AMD Trials Advance Into 2026

EyePoint reports 97% revenue decline to $0.7M in Q1 2026 amid $84.8M net loss, but maintains $223M cash runway through Q4 2027 as DURAVYU Phase 3 trials advance.
EYPTregulatory approvalretinal diseases
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Ocular Therapeutix Plans June Investor Day Amid Promising AMD Trial Data

Ocular Therapeutix schedules June 17 investor day in NYC while reporting positive Week 52 data from SOL-1 Phase 3 trial of AXPAXLI for wet AMD treatment.
OCULPhase 3 trialInvestor Day
BenzingaBenzinga··Not Specified

Outlook Therapeutics Launches Capital Raise Through Public Stock Offering

Outlook Therapeutics launches best-efforts public offering of stock and warrants with H.C. Wainwright as placement agent, subject to market conditions.
OTLKwarrantspublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

EyePoint Grants Stock Options to New Hires as DURAVYU Phase 3 Trials Advance

EyePoint grants stock options to six new employees as clinical program advances toward Phase 3 topline data for wet AMD therapy.
EYPTPhase 3 trialsbiopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Eyepoint, Inc.

EyePoint Pharmaceuticals Names Veteran Ophthalmology Executive Campbell as CCO

EyePoint Pharmaceuticals appoints Michael Campbell as Chief Commercial Officer. The ophthalmology veteran brings 30+ years of experience to lead commercial strategy for DURAVYU ahead of 2026 clinical data.
EYPTPhase 3 clinical trialophthalmology
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Ocular Therapeutix to Release SOL-1 Phase 3 Results for Wet AMD Treatment

Ocular Therapeutix announces Phase 3 results for SOL-1 wet AMD treatment on February 17, 2026. AXPAXLI data presentation follows at Macula Society Annual Meeting.
OCULPhase 3 clinical trialbiopharmaceutical